Comparison of Two Different Safety Distances to Sapheno-femoral Junction for EndoVenous Laser Ablation Treatment of Great Saphenous Vein Incompetence: a Prospective Randomized Double-blind Study
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Medical University of Vienna
- Enrollment
- 184
- Locations
- 2
- Primary Endpoint
- Number of Complete obliteration of the GSV or absence of an open saphenous stump at the SFJ 3 years after EVLA
Study Overview
Brief Summary
Chronic venous disease is one of the most common diseases in the western world and worldwide with a prevalence of 83,6%. It is a chronic progressive disease, which causes a significant burden on health systems, treatment and care of these patients. Recurrence of varicose veins after successful treatment remains a problem and has been reported in up to 30% of patients after endovenous laser ablation (EVLA), which is the recommended treatment of choice for incompetence of the truncal veins. The aim of this project is to investigate a variation of the EVLA, which has the potential to reduce the recurrence rate in the long-term. If this assumption is true, the investigators expect reduction of costs in the health system and improved quality of life for individual patients.The primary objective of the project is the evaluation of long-term anatomical effectiveness of EVLA treatment with and without keeping a distance to sapheno-femoral junction (SFJ), defined as complete obliteration of the great saphenous vein (GSV) or absence of an open saphenous stump at the SFJ after 3 years. Secondary objectives are:
- . Evaluation of the effectiveness of EVLA treatment with and without keeping a distance to SFJ, measured as duplex sonographic reflux (≥ 0,5 sec) in the GSV or any other axial vein at the SFJ after 1 year and 3 years.
- . Evaluation of the anatomical effectiveness of EVLA treatment with and without keeping a distance to SFJ, measured as the length of the open saphenous stump (in centimeters) after 1 year and 3 years.
- . Assessment of quality of life 3 months, 1 year and 3 years after EVLA.
- . Evaluation of the clinical efficacy and tolerability measured as a clinical score at 3 months, 1 year and 3 years after EVLA.
- . Safety assessment measured as the number of thromboembolic events 1 week and 3 months after EVLA.This project is planned as a prospective randomized parallel group double-blind study.
For the assessment of efficacy and safety parameters, clinical examinations and duplex sonographic examinations will be performed 3 months, 1 year and 3 years after the intervention.
For the assessment of tolerability endpoints, clinical scores and quality of life score will be performed 3 months, 1 year and 3 years after EVLA. Clinical scores include Clinical, Etiologic, Anatomical, and Pathophysiological Classification (CEAP) and Venous Clinical Severity Scoring (VCSS) and for evaluation of quality of life Aberdeen Varicose Veins Questionnaire (AVVQ) will be used.
Detailed Description
Introduction and background information Chronic venous disease is one of the most common diseases in the western world and worldwide with a prevalence of 83,6%. It is a chronic progressive disease, which causes a significant burden on health systems, treatment and care of these patients.
There are different methods for treatment of insufficiency of the GSV, which have good evidence: open surgery and minimally invasive techniques including ultrasound-guided foam sclerotherapy (UGFS), radiofrequency ablation (RFA) and endovenous laser ablation (EVLA). UGFS and thermal ablation techniques such as EVLA have become widely used alternatives to surgery for the treatment of venous reflux. The safety and efficacy of EVLA has been demonstrated in several studies. According to guidelines of the European Venous Forum (EVF), the International Union of Angiology (IUA) and the European Society for Vascular Surgery (ESVS) the treatment of GSV reflux with EVLA is recommended in preference to surgery, Grade of Recommendation 1A.
Rationale of the project Recurrence of varicose veins after successful treatment remains a problem and has been reported in up to 30% of patients after EVLA. Treatment with EVLA aims at complete obliteration of the vein in the treated area. According to the literature a safety distance of 1-2 cm from the sapheno-femoral junction (SFJ) is obligatory in all patients undergoing EVLA of the GSV. In earlier trials laser systems equipped with a bare fibre were used, which emit shorter wavelength of 810 nm antegrade with an absorption maximum in the range of haemoglobin. A new generation of laser devices with a wavelength of 1470 nm has been introduced in recent years. The absorption coefficient of water at 1470 nm is significantly higher than in the wavelength range of 810 - 1064 nm, which results in a much better control of the laser energy applied. The patented radial (360°) fibre ensures radial delivery of energy inducing homogenous photothermal destruction of the vein wall. By avoiding perforation of the vein wall and associated thermal irritation of the surrounding tissue, post-operative pain is minimized, as are ecchymosis and other side effects noticed with the previously used bare fibres.
In prospective studies it has been demonstrated that EVLA of the GSV using radial fibres has fewer side effects compared to EVLA of the GSV using bare fibre. It is not known whether the use of radial fibres results in a complete vascular closure of GSV up to the SFJ, and whether a remaining non-occluded vessel stump could be a cause of recurrence. Applying EVLA without keeping a distance of 1-2 cm to the SFJ is used with increasing frequency by many specialists, but there is no controlled data about this topic.
At our department the investigators use a 1470 nm laser with radial fibres without keeping a distance to SFJ and have no complications observed so far.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Masking Description
The blinding of the patients is facilitated by the same mode schedule and the same treatment performance for both allocations.
The patients will not be informed of their treatment allocation. The clinical investigator who will prepare the follow-up investigations will not have information about treatment allocation too. The blinded investigator will not have access to the full documentation of the study and to randomizing data.
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •. Age ≥ 18 years
- •. Duplex sonographic reflux in GSV ≥ 0,5 seconds
- •. Straight run of the GSV in the thigh
Exclusion Criteria
- •. Acute thromboembolic events
- •. Active cancer
- •. Postthrombotic syndrome from obstruction type
- •. Severe peripheral arterial occlusive disease (PAOD, ankle brachial index (ABI) ≤ 0.5)
- •. Pregnancy and breast feeding
- •. Incompetence of the anterior accessory great saphenous vein (AAGSV)
- •. Intolerance for compression stockings
- •. Contraindications for local anesthesia or general anaesthesia
Outcomes
Primary Outcomes
Number of Complete obliteration of the GSV or absence of an open saphenous stump at the SFJ 3 years after EVLA
Time Frame: 3 years
Number of complete obliteration of the GSV or absence of an open saphenous stump will be assessed by duplex-sonographic investigation
Secondary Outcomes
- Number of GSV with Duplex sonographic reflux (≥ 0,5 sec) or any other axial vein at the SFJ(1 year and 3 years)
- Length of the open saphenous stump (in centimeters)(1 year and 3 years)
- Satisfaction assessed by the QOL(3 months, 1 year, 3 years)
- points of Clinical score(3 months, 1 year, 3 years)
- Incidence of treatment-emergent adverse events assessed as Number of thromboembolic events(1 week, 3 months)
Investigators
Stanislava Tzaneva
Principal Investigator, Clinical Professor
Medical University of Vienna
